To elucidate the safety profile and symptom-modifying effect of Alflutop and diacerein in the treatment of Kellgren-Lawrence Stages II-III knee osteoarthrosis ( OA ) in patients with oxalate nephropathy and Stages I-II chronic kidney disease ( CKD ) and to refine the effect of these drugs on urinary syndrome and renal function as compared to a response to nonsteroidal anti-inflammatory drugs -- cyclooxygenase inhibitors ( diclofenac ) .